Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Early blood pressure treatment may postpone true hypertension


’Proof of principle’ trial shows promise, but it’s too early to recommend drug treatment for all with pre-hypertension

A new study offers intriguing insight into the possibility of postponing hypertension among the 59 million Americans whose blood pressure is slightly high. If confirmed, the concept may offer a chance to keep many people from facing the high risk of heart disease and stroke that currently confronts the 65 million Americans with hypertension. But for now, the researchers call it a "proof of principle" result and note that this is the first study to address the issue thoroughly.

The results come from a rigorous four-year study of 772 people with a condition called pre-hypertension, in which blood pressure is elevated over normal levels but not high enough to meet the criteria for a formal diagnosis of hypertension.

University of Michigan Cardiovascular Center researcher Stevo Julius, M.D., Sc.D., and colleagues will present the data today at the American College of Cardiology annual meeting and in a simultaneous paper in the New England Journal of Medicine.

For the first two years of the study, half the patients received a placebo and half received a blood pressure drug called candesartan. For the next two years, all participants received a placebo, allowing the researchers to detect any lasting effects from drug treatment. All participants received guidance on diet and exercise to control blood pressure, and all had regular blood pressure measurements at home and in clinic visits. The participants were randomized to their study group and the researchers were blinded as to which group participants were in.

Throughout the study, there was a significant difference between the two groups in the development of hypertension. By study’s end, the participants who received the blood pressure drug for two years and then stopped had a 15.6 percent lower risk of developing hypertension relative to those who received placebo for four years. The researchers suspect the drug treatment interrupted blood-vessel processes that raise blood pressure, a phenomenon that has been seen previously in animal studies.

"This study, which is the first of its kind, shows that postponement of hypertension onset through medical treatment is feasible, and without side effects," says Julius, an active emeritus professor of cardiovascular medicine at the U-M Medical School. "However, the effect is moderate, and further studies in younger people and over longer periods of time are needed in order to demonstrate clinical usefulness."

The study, called the Trial of Preventing Hypertension or TROPHY study, was funded by AstraZeneca, the pharmaceutical company that makes candesartan and sells it as ATACAND (candesartan cilexetil).

Julius and his colleagues proposed the study design to AstraZeneca, which agreed to fund and organize the study. The data were collected and compiled by the company, and then provided to Julius and his colleagues for analysis.

The study involved adults between the ages of 30 and 65 who were enrolled at 71 centers in the United States. The average age was 48, and 60 percent of participants were men.

At the beginning of the study, all had average blood pressure readings that included either a systolic (top number) reading between 130 and 139 mmHg, or a diastolic (bottom number) reading between 80 and 89 mmHg. This range is considered pre-hypertensive.

The study’s main goal was to see how many participants from each group (drug vs. placebo) progressed to having full-blown hypertension, defined as a systolic reading over 140 mmHg or a diastolic reading over 90 mmHg, at three of their clinic visits during the study or at the four-year visit.

At the end of two years, 40 percent of the 381 participants who received only placebo had developed hypertension, compared with 13.6 percent of the 391 participants who had received candesartan for those two years. By the end of four years, 63 percent of the participants who received only placebo had developed hypertension, compared with 53 percent of the participants who received candesartan for two years followed by placebo for two years. There was no difference between the groups in adverse events, serious or otherwise, suggesting no side effects from the drug.

Julius and his colleagues emphasize that the study addresses one of hypertension’s most insidious characteristics: the rapid pace at which it develops and worsens, setting individuals up for heart disease and stroke.

"Rising blood pressure is not a linear process. It goes exponentially, and as blood vessels start to respond to higher pressure, they develop hypertrophy, which causes further aggravation of hypertension," Julius explains. "The concept behind this study, based on a phenomenon observed in animal studies, is that by preventing the escalating effect on the blood vessels, one can interrupt the process of hypertension."

The need for better strategies for pre-hypertensive people is urgent, Julius adds. "What we have done so far is tell them to exercise and watch their diet, but these measures have not had any impact on public health. Rates of pre-hypertension are actually increasing," he says. "The time has come to look at this problem in a new way, and that is what this study set out to do. It’s not the answer for everything, but it looks pretty promising, though one would like to see stronger results."

Now, the researchers say, more studies of pre-hypertension are needed, to complement the large amount of research on end-stage hypertension that has been carried out in recent years.

According to the American Heart Association, high blood pressure was listed as a primary or contributing cause of death in about 277,000 American deaths in the year 2003. About 69 percent of people who have a first heart attack, 77 percent of those who have a first stroke, and 74 percent of patients with heart failure have blood pressure higher than 140/90 mmHg.

Kara Gavin | EurekAlert!
Further information:

More articles from Studies and Analyses:

nachricht Rutgers-led innovation could spur faster, cheaper, nano-based manufacturing
14.02.2018 | Rutgers University

nachricht New study from the University of Halle: How climate change alters plant growth
12.01.2018 | Martin-Luther-Universität Halle-Wittenberg

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Space observation with radar to secure Germany's space infrastructure

Satellites in near-Earth orbit are at risk due to the steady increase in space debris. But their mission in the areas of telecommunications, navigation or weather forecasts is essential for society. Fraunhofer FHR therefore develops radar-based systems which allow the detection, tracking and cataloging of even the smallest particles of debris. Satellite operators who have access to our data are in a better position to plan evasive maneuvers and prevent destructive collisions. From April, 25-29 2018, Fraunhofer FHR and its partners will exhibit the complementary radar systems TIRA and GESTRA as well as the latest radar techniques for space observation across three stands at the ILA Berlin.

The "traffic situation" in space is very tense: the Earth is currently being orbited not only by countless satellites but also by a large volume of space...

Im Focus: Researchers Discover New Anti-Cancer Protein

An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from the Biozentrum, University of Basel, report in “Nature” that LHPP can also serve as a biomarker for the diagnosis and prognosis of liver cancer.

The incidence of liver cancer, also known as hepatocellular carcinoma, is steadily increasing. In the last twenty years, the number of cases has almost doubled...

Im Focus: Researchers at Fraunhofer monitor re-entry of Chinese space station Tiangong-1

In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.

Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...

Im Focus: Alliance „OLED Licht Forum“ – Key partner for OLED lighting solutions

Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.

They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...

Im Focus: Mars' oceans formed early, possibly aided by massive volcanic eruptions

Oceans formed before Tharsis and evolved together, shaping climate history of Mars

A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

New solar solutions for sustainable buildings and cities

23.03.2018 | Event News

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

Latest News

For graphite pellets, just add elbow grease

23.03.2018 | Materials Sciences

Unique communication strategy discovered in stem cell pathway controlling plant growth

23.03.2018 | Agricultural and Forestry Science

Sharpening the X-ray view of the nanocosm

23.03.2018 | Physics and Astronomy

Science & Research
Overview of more VideoLinks >>>